BioCardia Inc (BCDA) just unveiled an announcement.
BioCardia, Inc. has joined forces with StemCardia, Inc. to propel a pioneering cell therapy for heart failure. With this exclusive partnership, BioCardia becomes the sole delivery partner for StemCardia’s promising stem cell product as it moves through FDA investigational new drug application processes and gears up for initial clinical trials. This strategic alliance aims to blend BioCardia’s delivery expertise with StemCardia’s cell and gene therapy innovations to tackle heart disease.
See more insights into BCDA stock on TipRanks’ Stock Analysis page.
